Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06904378 | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors | recruiting | Phase 1 | 48 | Shenzhen Xinhe BiomedicalINDUSTRY | 1 | May 19, 2026 |
| clinicaltrials |
| NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 55 | West China HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07594548 | Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | not yet recruiting | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma(NYHCC) | not yet recruiting | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07493044 | An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | not yet recruiting | Phase 1 | 192 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07580261 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | recruiting | Phase 1 | 22 | University of California, IrvineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04627246 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | active not recruiting | Phase 1 | 14 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07417488 | GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas | recruiting | Phase 1 | 18 | Thomas Jefferson UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07164313 | A Study of ZW251 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07478302 | A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 36 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Washington University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | recruiting | Phase 1 | 15 | University of HawaiiOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 193 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04605731 | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | active not recruiting | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05842174 | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma(TAQE) | recruiting | Phase 1 / Phase 2 | 93 | VA Office of Research and DevelopmentFED | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04220827 | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer | active not recruiting | Phase 1 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05257993 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 71 | Onconic Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06454383 | Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07114861 | The KN510713 Study in Combination With mFOLFIRINOX | recruiting | Phase 1 / Phase 2 | 30 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07522411 | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 100 | BinYong LiangOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05003895 | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06639724 | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | recruiting | Phase 1 | 36 | University of California, San DiegoOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | recruiting | Phase 1 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 19, 2026source: clinicaltrials